安罗替尼联合多西他赛二线治疗驱动基因阴性晚期非小细胞肺癌的疗效及安全性  

Efficacy and Safety of Anrotinib Combined with Docetaxel in Second-line Treatment of Advanced Non-small Cell Lung Cancer with Negative Driver Gene

作　　者：马慧利[1] 任中海[1] 尚付梅 张敬伟[1] 李长生[1] 冀叶[1] 袁小笋 MA Huili;REN Zhonghai;SHANG Fumei(Nanyang Central Hospital,Nanyang,473000)

机构地区：[1]河南省南阳市中心医院,473000

出　　处：《实用癌症杂志》2023年第3期476-480,484,共6页The Practical Journal of Cancer

摘　　要：目的 探讨安罗替尼联合多西他赛二线治疗驱动基因阴性晚期非小细胞肺癌的疗效及安全性。方法 收集驱动基因阴性晚期非小细胞肺癌患者78例,采用随机数字表法进行分组,即对照组、观察组,均39例。对照组予以单纯多西他赛药物治疗,观察组予以安罗替尼联合多西他赛药物治疗。统计近期临床疗效、血清相关因子、无进展生存期(progression-free survival, PFS)、总生存期(Overall survival, OS)、不良反应发生率。结果 观察组与对照组客观缓解率、疾病控制率比较,差异均有统计学意义(χ^(2)=5.186,P=0.023;χ^(2)=6.189,P=0.014)。观察组患者Ep-CAM、sICAM 1、CAM、ICAM-1、E-Cad水平均明显低于对照组患者(t=13.302,P=0.000;t=7.571,P=0.000;t=17.686,P=0.000;t=10.546,P=0.000;t=32.403,P=0.000)。观察组患者FGF、VEGF、MMP-9、MMP-2水平均明显低于对照组患者(t=8.408,P=0.000;t=36.591,P=0.000;t=15.834,P=0.000;t=21.994,P=0.000),Casp-8水平明显高于对照组(t=22.197,P=0.000)。2组患者不良反应发生率比较,P>0.05。观察组中位PFS为3.62月,对照组中位PFS为2.22月,2组患者中位PFS进行比较,HR=0.32,95%CI:0.18~0.57,P<0.05。观察组中位OS为6.00月,对照组中位OS为4.40月,2组中位OS进行比较,HR=0.44,95%CI:0.25~0.79,P<0.05。结论 安罗替尼联合多西他赛二线治疗驱动基因阴性晚期非小细胞肺癌患者,疗效理想,可有效改善患者生存情况,安全性高。Objective To investigate the efficacy and safety of anrotinib combined with docetaxel in the second-line treatment of driver negative advanced non-small cell lung cancer.Methods 78 patients with driver negative advanced non-small cell lung cancer were collected and grouped by random number table method, 39 cases in the control group and the observation group.The control group was treated with docetaxel alone, and the observation group was treated with anrotinib combined with docetaxel.The recent clinical efficacy, serum-related factors, progression-free survival(PFS),overall survival(OS),and incidence of adverse reactions were analyzed.Results There were significant differences in objective remission rate and disease control rate between the 2 groups(χ^(2)=5.186,P=0.023;χ^(2)=6.189,P=0.014).The levels of Ep-CAM,sICAM 1,CAM,ICAM-1 and E-Cad in the observation group were significantly lower than those in the control group(t=13.302,P=0.000;t=7.571,P=0.000;t=17.686,P=0.000;t=10.546,P=0.000;t=32.403,P=0.000).The levels of FGF,VEGF,MMP-9 and MMP-2 in the observation group were significantly lower than those in the control group(t=8.408,P=0.000;t=36.591,P=0.000;t=15.834,P=0.000;t=21.994,P=0.000),Casp-8 level was significantly higher than that of the control group(t=22.197,P=0.000).The incidence of adverse reactions between the 2 groups was compared, P>0.05.The median PFS of the observation group was 3.62 months, and the median PFS of the control group was 2.22 months.The median PFS of the 2 groups were compared, HR=0.32,95%CI:0.18-0.57,P<0.05.The median OS of the observation group was 6.00 months, and that of the control group was 4.40 months.The median OS of the 2 groups was compared, HR=0.44,95%CI:0.25~0.79,P<0.05.Conclusion Androtinib combined with docetaxel in the second-line treatment of patients with driver-negative advanced non-small cell lung cancer has ideal efficacy and can effectively improve the survival of patients with high safety.

关 键 词：晚期非小细胞肺癌 驱动基因阴性 安罗替尼 多西他赛 临床疗效 安全性 

分 类 号：R734.2[医药卫生—肿瘤]